<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02295969</url>
  </required_header>
  <id_info>
    <org_study_id>SL74.14</org_study_id>
    <nct_id>NCT02295969</nct_id>
  </id_info>
  <brief_title>Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis</brief_title>
  <official_title>An Observational Study of ORALAIR® (Grass Pollen Allergen Extract From: Cocksfoot, Sweet Vernal, Rye Grass, Meadow Grass, Timothy) Tablet for Sublingual Use in Children 5 to 9 Years of Age With Grass-pollen-induced Allergic Rhinitis With or Without Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stallergenes Greer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Venn Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stallergenes Greer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and tolerability of ORALAIR in children 5 to 9 years of age during the first 30 days
      of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to further describe the safety and tolerability of ORALAIR
      tablets in children 5 to 9 years of age with grass-pollen-induced allergic rhinitis with or
      without conjunctivitis.

      Patients are followed for safety and tolerability during the first 30 treatment days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">July 3, 2017</completion_date>
  <primary_completion_date type="Actual">July 3, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All adverse events that started on or after the day the first dose of Oralair</measure>
    <time_frame>During 30 days after the date of the first dose</time_frame>
  </primary_outcome>
  <enrollment type="Actual">307</enrollment>
  <condition>Allergy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oralair</intervention_name>
    <description>Observational study, Oralair is used as prescribed by the prescriber phycisian.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatients, children 5 to 9 years of age prescribed ORALAIR for the treatment of
        grass-pollen-induced allergic rhinitis with or without conjunctivitis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Allergen immunotherapy naive male or female outpatients aged 5 to 9 years (inclusive)
        prescribed ORALAIR.

        Exclusion Criteria:

        Patients already participating in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Klinikum Augsburg, Klinik für Kinder und Jugendliche</name>
      <address>
        <city>Augsburg</city>
        <state>Bavaria</state>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>November 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rhinitis</keyword>
  <keyword>Conjunctivitis</keyword>
  <keyword>Grass pollen</keyword>
  <keyword>Sublingual tablet</keyword>
  <keyword>Allergen immunotherapy</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

